Medications Archives | Best Allergy Medicine HQ

Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

13/11/2020 mediabest Medications

VANCOUVER, British Columbia, Oct. 30, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or

Update on CALAVI Phase II Trials for Calquence in Patients Hospitalised with Respiratory Symptoms of COVID-19

12/11/2020 mediabest Medications

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not

FDA Approves Eysuvis

31/10/2020 mediabest Medications

FDA Approves Eysuvis (loteprednol etabonate) Ophthalmic Suspension for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

FDA Authorises Restart of the COVID-19 AZD1222 Vaccine US Phase III Trial

27/10/2020 mediabest Medications

23 October 2020 — Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators

ViiV Healthcare Announces Analysis Showing no Antiretroviral Therapy Interruptions Due to COVID-19 Across its Clinical Development Programme for Investigational, Long-Acting Cabotegravir and Rilpivirine

21/10/2020 mediabest Medications

21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

12/10/2020 mediabest Medications

FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 8, 2020– The New England Journal of Medicine (NEJM) today published the final results from the National Institute of

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

07/10/2020 mediabest Medications

NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE) October 07, 2020 — Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO),

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

19/09/2020 mediabest Medications

HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing

Trenbolone Acetate efficiency for male and females athletes

27/05/2020 mediabest Medications

Trenbolone Acetate is a pharmacological modification of Nandrolone with acetate. This combination of substances allows the drug to demonstrate high activity, but

Do you take warfarin? Time of day might not matter

17/01/2020 mediabest Medications

(HealthDay)—Patients taking the blood thinner warfarin have been told that it should be taken at night, but a new study